Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.

Journal article

OBJECTIVES: To evaluate the cost effectiveness of 40 mg simvastatin daily continued for life in people of different ages with differing risks of vascular disease. DESIGN: A model developed from a randomised trial was used to estimate lifetime risks of vascular events and costs of treatment and hospital admissions in the United Kingdom. SETTING: 69 hospitals in the UK. PARTICIPANTS: 20,536 men and women (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes. INTERVE...

Expand abstract

Authors: Mihaylova, B; Briggs, A; Armitage, J; Parish, S; Gray, A

• Publication status: Published
• Journal: BMJ (Clinical research ed.)
• Volume: 333
• Issue: 7579
• Pages: 1145
• Publication date: 2006-12-01
• DOI: 10.1136/bmj.38993.731725.be
• EISSN: 1756-1833
• ISSN: 0959-8138
• Language: English
• Keywords: Risk Factors; Heart Protection Study Collaborative; Quality-Adjusted Life Years; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Female; Adult; Arterial Occlusive Diseases; Simvastatin; Male; Aged, 80 and over; Aged; Cost-Benefit Analysis; Coronary Disease; Diabetic Angiopathies; Life Expectancy; Middle Aged; Humans